Denali Advisors LLC Has $12.40 Million Position in Gilead Sciences, Inc. (GILD)

Denali Advisors LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 160,603 shares of the biopharmaceutical company’s stock after acquiring an additional 5,200 shares during the quarter. Gilead Sciences accounts for about 1.8% of Denali Advisors LLC’s investment portfolio, making the stock its 25th biggest position. Denali Advisors LLC’s holdings in Gilead Sciences were worth $12,400,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Gilead Sciences during the second quarter worth about $132,000. Brand Asset Management Group Inc. bought a new stake in Gilead Sciences during the second quarter worth about $139,000. Wealthsource Partners LLC bought a new stake in Gilead Sciences during the second quarter worth about $206,000. Aspen Investment Management Inc bought a new stake in Gilead Sciences during the first quarter worth about $207,000. Finally, Kaizen Advisory LLC grew its stake in Gilead Sciences by 142.1% during the second quarter. Kaizen Advisory LLC now owns 3,063 shares of the biopharmaceutical company’s stock worth $217,000 after buying an additional 1,798 shares during the last quarter. 77.99% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $74.16, for a total value of $3,708,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at $227,505,229.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 150,000 shares of company stock worth $11,502,500 over the last 90 days. 1.16% of the stock is currently owned by company insiders.

Several brokerages have weighed in on GILD. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Monday, October 1st. They set an “overweight” rating and a $87.00 price objective on the stock. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, September 29th. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, September 28th. Zacks Investment Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 25th. Finally, Piper Jaffray Companies set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, September 12th. Twelve research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $88.24.

Shares of NASDAQ GILD opened at $76.40 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $64.27 and a fifty-two week high of $89.54. The company has a market capitalization of $100.09 billion, a P/E ratio of 8.94, a price-to-earnings-growth ratio of -3.92 and a beta of 1.01. The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period in the prior year, the business posted $2.56 earnings per share. Gilead Sciences’s revenue was down 20.9% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 27th. Investors of record on Friday, September 14th were issued a $0.57 dividend. The ex-dividend date of this dividend was Thursday, September 13th. This represents a $2.28 annualized dividend and a yield of 2.98%. Gilead Sciences’s dividend payout ratio is currently 26.64%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.

Leave a Reply